These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8006248)

  • 1. Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients.
    Hoencamp E; Haffmans PM; Dijken WA; Hoogduin CA; Nolen WA; van Dyck R
    J Affect Disord; 1994 Mar; 30(3):219-27. PubMed ID: 8006248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brofaromine vs. maprotiline plus lithium in treatment-resistant depressed outpatients.
    Hoencamp E; Haffmans PM
    Psychiatry Res; 1991 Mar; 36(3):333-5. PubMed ID: 2062972
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of (non-) response in depressed outpatients treated with a three-phase sequential medication strategy.
    Hoencamp E; Haffmans PM; Duivenvoorden H; Knegtering H; Dijken WA
    J Affect Disord; 1994 Aug; 31(4):235-46. PubMed ID: 7989638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    J Affect Disord; 1994 Oct; 32(2):105-14. PubMed ID: 7829762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
    Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
    J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
    Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
    Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
    Schiwy W; Heath WR; Delini-Stula A
    J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.
    Volz HP; Faltus F; Magyar I; Möller HJ
    J Affect Disord; 1994 Mar; 30(3):209-17. PubMed ID: 8006247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year.
    Möller HJ; Volz HP
    J Affect Disord; 1992 Nov; 26(3):163-72. PubMed ID: 1460166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of moclobemide compared with maprotiline in treatment of major depressive disorder. A double-blind multicenter study with parallel groups.
    Steinmeyer EM; Vorbach EU; Arnoldt KH
    Pharmacopsychiatry; 1993 Nov; 26(6):246-53. PubMed ID: 8127929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response.
    Benkert O; Szegedi A; Wetzel H; Staab HJ; Meister W; Philipp M
    Acta Psychiatr Scand; 1997 Apr; 95(4):288-96. PubMed ID: 9150822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brofaromine in elderly major depressed patients--a comparative trial versus imipramine.
    Möller HJ; Volz HP
    Eur Neuropsychopharmacol; 1993 Dec; 3(4):501-10. PubMed ID: 8111223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.
    Fahlén T; Nilsson HL; Borg K; Humble M; Pauli U
    Acta Psychiatr Scand; 1995 Nov; 92(5):351-8. PubMed ID: 8619339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline.
    Szegedi A; Wetzel H; Angersbach D; Philipp M; Benkert O
    J Affect Disord; 1997 Sep; 45(3):167-78. PubMed ID: 9298430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brofaromine versus imipramine in in-patients with major depression--a controlled trial.
    Volz HP; Gleiter CH; Möller HJ
    J Affect Disord; 1997 Jul; 44(2-3):91-9. PubMed ID: 9241569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression.
    de Jonghe F; Ravelli DP; Tuynman-Qua H
    Pharmacopsychiatry; 1991 Mar; 24(2):62-7. PubMed ID: 1852793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic superiority of maprotiline versus doxepin in geriatric depression.
    Gwirtsman HE; Ahles S; Halaris A; DeMet E; Hill MA
    J Clin Psychiatry; 1983 Dec; 44(12):449-53. PubMed ID: 6361005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression.
    König F; Wolfersdorf M; Löble M; Wössner S; Hauger B
    Pharmacopsychiatry; 1997 Jul; 30(4):125-7. PubMed ID: 9271778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.